Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0F3NH
|
|||
| Former ID |
DIB012779
|
|||
| Drug Name |
Balaglitazone
|
|||
| Synonyms |
DRF-2593; NN-2344; DRF-2593-307; NNC-61-0645
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Type-1 diabetes [ICD-11: 5A10; ICD-9: 250] | Phase 3 | [1] | |
| Company |
Dr Reddy's Research Foundation
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H17N3O4S
|
|||
| Canonical SMILES |
CN1C(=NC2=CC=CC=C2C1=O)COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4
|
|||
| InChI |
1S/C20H17N3O4S/c1-23-17(21-15-5-3-2-4-14(15)19(23)25)11-27-13-8-6-12(7-9-13)10-16-18(24)22-20(26)28-16/h2-9,16H,10-11H2,1H3,(H,22,24,26)
|
|||
| InChIKey |
IETKPTYAGKZLKY-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 199113-98-9
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00515632) Efficacy and Safety of Treatment With Balaglitazone in Type 2 Diabetes Patients on Stable Insulin Therapy. U.S. National Institutes of Health. | |||
| REF 2 | Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma () agonist.Mini Rev Med Chem.2012 Feb;12(2):87-97. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.